|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||70.18 - 71.39|
|52 Week Range||36.88 - 73.00|
|Beta (5Y Monthly)||0.20|
|PE Ratio (TTM)||80.84|
|Forward Dividend & Yield||1.20 (1.85%)|
|Ex-Dividend Date||Sep 28, 2022|
|1y Target Est||86.20|
Subscribe to Yahoo Finance Plus to view Fair Value for ESALY
Lars Lannfelt had a key role in developing a drug that has shown some promise in tackling Alzheimer’s
Data from a phase III early symptomatic Alzheimer's disease study shows that Eli Lilly's (LLY) donanemab leads to a significant reduction of amyloid buildup in the brain and P-tau in the blood after six months.
Biogen stock surged Wednesday after partner Eisai unveiled Alzheimer's treatment test results that two doctors reportedly described as "magnificent."